Evogene Ltd. (NASDAQ:EVGN) Stock Short Interest Drops 93.2%

Evogene Ltd. (NASDAQ:EVGN – Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totaling 63,883 shares, a decrease of 93.2% from the September 30th total of 932,725 shares. Based on an average daily volume of 244,058 shares, the short-interest ratio is presently 0.3 days. Currently, 0.8% of the shares of the stock are short sold.

Evogene Stock Up 2.9%

EVGN stock traded up $0.01 during mid-day trading on Wednesday, reaching $0.37. 40,403 shares of the company traded hands, compared to its average volume of 1,100,521. The stock has a market cap of $3.26 million, a price-to-earnings ratio of -0.41 and a beta of 1.44. Evogene has a fifty-two week low of $0.35 and a fifty-two week high of $1.33. The firm’s 50 day moving average price is $0.46 and its 200 day moving average price is $0.68.

Insider Buying and Selling

In other news, Director Leon Recanati acquired 460,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was bought at an average price of $0.64 per share, with a total value of $294,400.00. Following the completion of the purchase, the director directly owned 1,343,886 shares of the company’s stock, valued at $860,087.04. This represents a 52.04% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research report on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on Evogene

Evogene Company Profile

(Get Free Report)

Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms.

Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.

Further Reading

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.